Lannett Receives FDA Approval for Phentermine

Lannett Company has received approval from the FDA for the abbreviated new drug application (ANDA) of Phentermine HCl tablets 37.5 mg.

The company expects to commence marketing this product in June 2005. Phentermine HCl is indicated for the short-term management of obesity and is the generic equivalent of Adipex-P, marketed by Gate Pharmaceuticals, a division of Teva Pharmaceutical.

According to NDC Health, the total U.S. market for Phentermine HCl 37.5 mg tablets is approximately $84 million. Currently, there are five other generic suppliers marketing this product.